Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 8-arm NCT04913337

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Sponsor: Merck Sharp & Dohme LLC

Conditions Breast Cancer Cervical Cancer Cholangiocarcinoma Colorectal Cancer Endocervical Cancer Esophageal Cancer Gastric Cancer Glioblastoma Melanoma Mesothelioma Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Ductal Adenocarcinoma Renal Cell Carcinoma Squamous Cell Carcinoma of Head and Neck

Interventions NGM707 NGM707 plus pembrolizumab (KEYTRUDA®)

Updated 13 times since 2021 Last updated: Sep 30, 2024 Started: Jun 9, 2021 Primary completion: Feb 28, 2025 Completion: Jul 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Breast Cancer and Cervical Cancer and is currently ongoing. Merck Sharp & Dohme LLC leads this study, which shows 13 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

13 versions recorded

Dec 2025 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Nov 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 8 earlier versions

Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE1_PHASE2
Mar 2022 — May 2022 [monthly]

Recruiting PHASE1_PHASE2
Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE1_PHASE2
Oct 2021 — Jan 2022 [monthly]

Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jun 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
NGM Biopharmaceuticals, Inc

Data source: NGM Biopharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Baltimore, United States , Blacksburg, United States , Boston, United States , Dallas, United States , Grand Rapids, United States , Greenville, United States , Houston, United States , Lone Tree, United States , Los Angeles, United States and 13 more locations